CRISPR Genome Editing Solutions From Discovery To Clinic

The CRISPR-associated gene editing system has emerged as a preeminent platform for the development of innovative gene and cell therapies. Direct delivery of the CRISPR ribonucleoprotein (RNP) complex, comprising single guide RNA (sgRNA) and Cas nucleases, offers a promising non-viral approach for clinical gene editing. However, the translation of this technology into therapeutic applications presents substantial challenges, including the design and manufacture of target-specific guides, the production of high-fidelity nucleases, and the comprehensive characterization of the RNP complex for safe and efficacious delivery.

To expedite the development of CRISPR-based therapeutics, Aldevron and Integrated DNA Technologies (IDT) have formed a strategic partnership. IDT brings extensive expertise in oligonucleotide chemistry and production for high-quality CRISPR gRNAs, while Aldevron offers cGMP manufacturing and characterization capabilities for CRISPR nucleases and RNP complexes. By combining our complementary strengths, we provide a comprehensive suite of services to support the clinical translation of CRISPR genome editing technologies.